Enabling Successful BLA Sample Testing and Regulatory Operations in China for a Swiss Biologics Company

End-to-end

Regulatory operations support aligned with NMPA requirements

Timely

coordination of sample testing and dossier submission activities

Proactive

risk mitigation to prevent Regulatory delays

Client Overview

A Switzerland-based biopharmaceutical company required Regulatory Affairs and Regulatory Operations support in China for a monoclonal antibody product undergoing the Biologics License Application (BLA) process. The client sought expert assistance in coordinating sample testing, dossier preparation, Regulatory communications, and submission activities while ensuring compliance with evolving China NMPA regulations and biologics registration requirements.

Background

As part of its China market access strategy, the client needed to complete sample testing and Regulatory documentation activities to support a BLA submission for a monoclonal antibody product. The process involved coordination with multiple stakeholders, alignment with NMPA technical requirements, and strict adherence to Regulatory timelines.

Given the complexity of China's biologics Regulatory framework and evolving NMPA expectations, the client required a trusted Regulatory partner capable of managing sample testing logistics, dossier readiness, Regulatory communications, and submission support to facilitate a smooth review process.

Services in Scope

BLA Sample Testing Coordination and Support

Regulatory Operations Management

Dossier Preparation and Submission Support

Sample Importation and Delivery to NMPA Test Centers

NMPA Communication and Query Management

Test Method Alignment and Risk Assessment

Regulatory Documentation Review and Compliance Support

Stakeholder Coordination Across Global Teams Tracking

Challenge

Tight Regulatory Timelines The client faced aggressive timelines for completing sample testing and Regulatory documentation activities required for BLA submission.

Evolving NMPA Requirements China's evolving Regulatory landscape required close monitoring of NMPA expectations and alignment with current biologics registration requirements.

Sample and Test Method Alignment Ensuring that testing methodologies met NMPA expectations was critical to avoiding delays and minimizing Regulatory risk.

Complex Stakeholder Coordination Managing communication among global stakeholders, test centers, and Health Authorities required strong Regulatory project management and operational oversight.

Solution

Sample Testing Coordination

Coordinated test sample preparation, logistics, and delivery to the designated NMPA testing center while ensuring compliance with local requirements.

Regulatory Documentation Support

Supported dossier preparation and documentation activities aligned with NMPA submission expectations and biologics Regulatory requirements.

NMPA Communication Management

Provided end-to-end query management and communication support with the NMPA testing center to ensure timely issue resolution and project continuity.

Risk Identification and Mitigation

Proactively identified potential Regulatory and technical risks and aligned testing methods with NMPA expectations to prevent delays during the review process.

Cross-Functional Stakeholder Coordination

Facilitated collaboration among global stakeholders to ensure the timely execution of testing, documentation, and Regulatory operations activities.

Impact

Freyr's support enabled the client to successfully complete critical sample testing and Regulatory operations activities required for the BLA review process in China.